MiMedx offers an unusually favorable risk-reward setup and a 3-of-4 earnings beat streak, but a sharp revenue decline and a death-cross-confirmed technical downtrend keep the position squarely in speculative, recovery-dependent territory.
Thesis pillars
- Sharp Revenue Decline→Stable
- Favorable Risk Reward→Stable
- Death Cross Downtrend Recovery→Stable
- +1 more pillar — see the Why tab for full reasoning
MiMedx Group, Inc (MDXG) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Wait for pullback to $4.04. Weak momentum; also below 200-day MA (death cross) — blocks BUY_NOW at $4.20. Engine's entry $4.04 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Value-trap signals (3/5): Revenue declining (-84.8% YoY), Margin compression (op margin -13930.7%), Material insider selling (4 sells, 0.15% of cap).
MiMedx Group develops and markets placental tissue allografts and, since 2024, animal-derived xenografts for wound care, burn, and surgical applications, manufacturing its PURION-processed products from donated birth tissue at facilities in Marietta and Kennesaw, Georgia. The... Read more
Wait for pullback to $4.04. Weak momentum; also below 200-day MA (death cross) — blocks BUY_NOW at $4.20. Engine's entry $4.04 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Value-trap signals (3/5): Revenue declining (-84.8% YoY), Margin compression (op margin -13930.7%), Material insider selling (4 sells, 0.15% of cap). Chart setup: RSI 56 mid-range, Bollinger mid-band. Earnings in 3 days. Wait until post-earnings. Score 4.9/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 3d<=7d. Suitability: speculative.
About MiMedx Group, Inc
About MiMedx Group, Inc
MiMedx sells placental tissue allografts under brands including EPIFIX, EPICORD, and AMNIOFIX, plus the bovine-collagen xenograft HELIOGEN launched in 2024, with domestic sales making up the vast majority of the company's revenue. Approximately 43% of 2025 sales came from customers belonging to the company's primary Group Purchasing Organizations and Integrated Delivery Networks, and roughly 26% moved through independent sales agents rather than a direct sales force.
MiMedx generates revenue from Wound Care and Surgical applications, manufacturing allografts through its patented PURION process at two Georgia facilities using donated placental tissue recovered through hospital partnerships, supplemented by exclusive distribution agreements signed in 2025 and early 2026 for products such as RegenKit-Wound Gel, NovaForm Wound Matrix, and Hydrelix Collagen Matrix. Reimbursement dynamics are central to the business: at the end of 2025, CMS announced a shift to a flat $127.14-per-square-centimeter reimbursement rate for skin substitutes across hospital outpatient and physician-office settings beginning January 1, 2026, replacing the prior ASP-plus-6% methodology. Internationally, MiMedx sells EPIFIX through distribution partner Gunze Medical in Japan, where the product holds the only amniotic tissue approval for wound treatment. The company also competes with tissue processors such as Surgenex, against whom MiMedx has pursued patent infringement litigation.
Show full overview
A regulatory dispute over AXIOFILL illustrates classification risk facing tissue processors: after 2023 FDA inspections produced Form 483 observations at both Georgia facilities, the agency issued a December 2023 warning letter and, in March 2024, a Request for Designation determination reaffirming that AXIOFILL does not qualify as a Section 361 human-tissue product. MiMedx has since sued the FDA in the Northern District of Georgia while continuing to market AXIOFILL during the litigation, an outcome that could reclassify the product under stricter drug or biologic pathways if the company's challenge fails.
See also: Healthcare · Biotechnology
From MiMedx Group, Inc's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-26Recent Developments — MiMedx Group, Inc
Latest news
- NEWS MiMedx Group, Inc (MDXG) Investor Outlook: Exploring a 52.42% Potential Upside Amidst Biotech Innovations - DirectorsTal — DirectorsTalk Interviews positive
- NEWS MDXG|MiMedx Group Inc|Price:4.200|Chg%:+0.070 - TradingKey — TradingKey positive
- NEWS MiMedx Group, Inc Revenue Breakdown – BOATS:MDXG - TradingView — TradingView neutral
- NEWS MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29 - GlobeNewswire — GlobeNewswire neutral
- NEWS MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29 - Yahoo Finance — Yahoo Finance neutral
Generated 2026-07-26T17:12:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -33.1% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $4.04. Weak momentum; also below 200-day MA (death cross) — blocks BUY_NOW at $4.20. Engine's entry $4.04 (1 ATR pullback) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Value-trap signals (3/5): Revenue declining (-84.8% YoY), Margin compression (op margin -13930.7%), Material insider selling (4 sells, 0.15% of cap). Chart setup: RSI 56 mid-range, Bollinger mid-band. Earnings in 3 days. Wait until post-earnings. Target $5.74 (+36.7%), stop $3.76 (−11.7%), A.R:R 3.1:1. Score 4.9/10, moderate confidence.
Take-profit target: $5.74 (+36.7% upside). Target $5.74 (+36.7%), stop $3.76 (−11.7%), A.R:R 3.1:1. Stop-loss: $3.76.
Value-trap signals (3/5): Revenue declining (-84.8% YoY), Margin compression (op margin -13930.7%), Material insider selling (4 sells, 0.15% of cap).
MiMedx Group, Inc trades at a P/E of 21.0 (forward 29.3). TrendMatrix value score: 6.8/10. Verdict: Buy (Wait for Entry).
11 analysts cover MDXG with a consensus score of 4.1/5. Average price target: $7.
What does MiMedx Group, Inc do?MiMedx Group develops and markets placental tissue allografts and, since 2024, animal-derived xenografts for wound...
MiMedx Group develops and markets placental tissue allografts and, since 2024, animal-derived xenografts for wound care, burn, and surgical applications, manufacturing its PURION-processed products from donated birth tissue at facilities in Marietta and Kennesaw, Georgia. The company sells primarily to U.S. hospitals, wound care clinics and physician offices through a direct sales force, independent sales agents, and distributors, with domestic sales making up the vast majority of revenue and international expansion focused on Japan through distribution partner Gunze Medical.